Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
This study has been completed.
Study NCT00001031   Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: November 2, 1999   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
rgp120/HIV-1MN
rgp120/HIV-1 SF-2
Additional drug interventions recognized in this trial
Adjuvants, Immunologic
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Biocine
Genentech


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services